The role of sodium-glucose co-transporter-2 inhibitors in frail older adults with or without type 2 diabetes mellitus.


Journal

Age and ageing
ISSN: 1468-2834
Titre abrégé: Age Ageing
Pays: England
ID NLM: 0375655

Informations de publication

Date de publication:
06 10 2022
Historique:
received: 18 03 2022
revised: 13 06 2022
entrez: 6 10 2022
pubmed: 7 10 2022
medline: 12 10 2022
Statut: ppublish

Résumé

Sodium-glucose co-transporter-2 (SGLT2) inhibitors offer significant outcome benefits beyond glucose lowering, including reduced risk of cardiovascular death, all-cause mortality, major adverse cardiovascular events, hospitalisations for heart failure and progression of renal disease. Considering these therapeutic effects, minimal incremental risk for hypoglycaemia and simplicity of administration, this drug class appears to be an attractive therapeutic option for older adults, and post hoc analysis of trial data provides support for the use of SGLT2 inhibitors in this population. Nevertheless, despite favourable clinical trial data, there has been some hesitance in clinical practice prescribing these drugs to older frail adults due to the limited therapeutic experience in this population and insufficient long-term safety data. In this review article, we evaluate the risk-benefit profile for the use of SGLT2 inhibitors in this population and suggest that rather than being a treatment to avoid, SGLT2 inhibitors should be considered a valid therapeutic option for older frail adults with or without diabetes.

Identifiants

pubmed: 36201329
pii: 6749364
doi: 10.1093/ageing/afac201
pmc: PMC9536439
pii:
doi:

Substances chimiques

Hypoglycemic Agents 0
Sodium-Glucose Transporter 2 0
Sodium-Glucose Transporter 2 Inhibitors 0
Sodium 9NEZ333N27
Glucose IY9XDZ35W2

Types de publication

Journal Article Review Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© The Author(s) 2022. Published by Oxford University Press on behalf of the British Geriatrics Society. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Références

N Engl J Med. 2019 Jan 24;380(4):347-357
pubmed: 30415602
Drugs Aging. 2016 Jul;33(7):511-22
pubmed: 27357173
Age Ageing. 2019 Nov 1;48(6):859-866
pubmed: 31579904
Diabetes Res Clin Pract. 2020 Apr;162:108078
pubmed: 32068097
Diabetes Res Clin Pract. 2019 Jul;153:138-144
pubmed: 31150722
Diabetes Care. 1997 Feb;20(2):135-41
pubmed: 9118760
N Engl J Med. 2021 Oct 14;385(16):1451-1461
pubmed: 34449189
J Gerontol A Biol Sci Med Sci. 2001 Mar;56(3):M146-56
pubmed: 11253156
Diabetes Ther. 2021 May;12(5):1227-1247
pubmed: 33830409
Endocr Pract. 2008 Sep;14(6):782-90
pubmed: 18996802
PLoS One. 2020 Mar 4;15(3):e0229621
pubmed: 32130249
JAMA Netw Open. 2021 Oct 1;4(10):e2130762
pubmed: 34705014
Lancet. 2019 Jan 5;393(10166):31-39
pubmed: 30424892
Ann Med. 2021 Dec;53(1):2072-2089
pubmed: 33107349
N Engl J Med. 2020 Oct 8;383(15):1436-1446
pubmed: 32970396
Circulation. 2021 Jan 26;143(4):326-336
pubmed: 33081531
JAMA Cardiol. 2021 May 1;6(5):499-507
pubmed: 33595593
BMJ Open. 2021 Apr 7;11(4):e045844
pubmed: 33827843
N Engl J Med. 2020 Oct 8;383(15):1413-1424
pubmed: 32865377
J Gerontol A Biol Sci Med Sci. 2017 Jul 1;72(7):877-884
pubmed: 27216811
JAMA Cardiol. 2021 Feb 1;6(2):148-158
pubmed: 33031522
N Engl J Med. 2017 Aug 17;377(7):644-657
pubmed: 28605608
Diabetes Care. 2015 Sep;38(9):1638-42
pubmed: 26294774
Eur J Prev Cardiol. 2017 Oct;24(15):1637-1645
pubmed: 28870145
N Engl J Med. 2019 Jun 13;380(24):2295-2306
pubmed: 30990260
J Am Geriatr Soc. 2016 Mar;64(3):543-52
pubmed: 27000327
N Engl J Med. 2015 Nov 26;373(22):2117-28
pubmed: 26378978
Circulation. 2020 Jan 14;141(2):100-111
pubmed: 31736328
Circulation. 2022 May 10;145(19):1460-1470
pubmed: 35394821
Diabetes Care. 2020 Feb;43(2):468-475
pubmed: 31843945
Ann Intern Med. 2022 Jun;175(6):820-830
pubmed: 35467935
Diabetes Care. 2021 Jan;44(Suppl 1):S168-S179
pubmed: 33298423
Cardiovasc Diabetol. 2020 Oct 23;19(1):185
pubmed: 33097060
Diabetes Res Clin Pract. 2020 Apr;162:108114
pubmed: 32165164
Postgrad Med J. 2006 Jun;82(968):357-62
pubmed: 16754702
N Engl J Med. 2020 Oct 8;383(15):1425-1435
pubmed: 32966714
N Engl J Med. 2019 Nov 21;381(21):1995-2008
pubmed: 31535829
Diabetes Care. 2001 Jun;24(6):1066-8
pubmed: 11375372
Diabetes Obes Metab. 2012 Nov;14(11):990-9
pubmed: 22651373
J Am Soc Nephrol. 2017 Feb;28(2):407-420
pubmed: 28143966
Circulation. 2020 Jan 14;141(2):90-99
pubmed: 31736335

Auteurs

Marc Evans (M)

Diabetes Resource Centre, University Hospital Llandough, Cardiff, UK.

Angharad R Morgan (AR)

Health Economics and Outcomes Research Ltd., Cardiff, UK.

Sarah Davies (S)

Woodlands Medical Centre, Cardiff, UK.

Hannah Beba (H)

NHS Leeds Clinical Commissioning Group, Leeds, UK.

William David Strain (WD)

Diabetes and Vascular Research Centre, University of Exeter Medical School, Exeter, UK.
The Academic Department of Healthcare for Older Adults, Royal Devon and Exeter Hospital, Exeter, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH